PMID- 30187578
OWN - NLM
STAT- MEDLINE
DCOM- 20190211
LR  - 20190215
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 101
IP  - 6
DP  - 2018 Dec
TI  - NKT cells - New players in CAR cell immunotherapy?
PG  - 750-757
LID - 10.1111/ejh.13170 [doi]
AB  - Low levels of peripheral blood natural killer T (NKT) cells in cancer patients 
      and a favorable outcome associated with a high number of tumor-infiltrating NKT 
      cells demonstrated in several studies indicated the important role of these 
      immune cells in the antitumor response. With effective antitumor immunity via 
      direct tumor lysis, cytokine modulation of effector cells and regulation of 
      immunosuppressive cells, type I NKT cells display interesting features/properties 
      for the rapidly developing chimeric antigen receptor (CAR) technology. Due to 
      their restriction to the monomorphic HLA-like molecule CD1d, but not to the 
      polymorphic human leukocyte antigen (HLA), NKT CAR cells show potential for 
      enabling autologous and allogeneic/off-the-shelf cancer immunotherapy. Promising 
      results were obtained in preclinical NKT CAR cell studies, but clinical trials 
      have not yet been conducted. In this review, we summarize the biological features 
      of NKT cells, their role in antitumor immunity and recent advances in the 
      development of NKT CAR cells.
CI  - (c) 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Kriegsmann, Katharina
AU  - Kriegsmann K
AUID- ORCID: 0000-0002-3620-1491
AD  - Department of Hematology, Oncology and Rheumatology, University Hospital 
      Heidelberg, Heidelberg, Germany.
FAU - Kriegsmann, Mark
AU  - Kriegsmann M
AD  - Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
FAU - von Bergwelt-Baildon, Michael
AU  - von Bergwelt-Baildon M
AD  - Department of Internal Medicine III, Ludwig Maximilian University, Munich, 
      Germany.
FAU - Cremer, Martin
AU  - Cremer M
AD  - Department of Hematology, Oncology and Rheumatology, University Hospital 
      Heidelberg, Heidelberg, Germany.
FAU - Witzens-Harig, Mathias
AU  - Witzens-Harig M
AD  - Department of Hematology, Oncology and Rheumatology, University Hospital 
      Heidelberg, Heidelberg, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20181009
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Biomarkers)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Receptors, Chimeric Antigen)
SB  - IM
MH  - Animals
MH  - Biomarkers
MH  - Disease Models, Animal
MH  - Drug Evaluation, Preclinical
MH  - Humans
MH  - *Immunotherapy, Adoptive/methods
MH  - Natural Killer T-Cells/cytology/*immunology/*metabolism
MH  - Phenotype
MH  - Receptors, Antigen, T-Cell/genetics/*metabolism
MH  - Receptors, Chimeric Antigen/genetics/*metabolism
OTO - NOTNLM
OT  - Natural killer T (NKT) cells
OT  - antitumor immunity
OT  - chimeric antigen receptor (CAR)
OT  - immunotherapy
EDAT- 2018/09/07 06:00
MHDA- 2019/02/12 06:00
CRDT- 2018/09/07 06:00
PHST- 2018/06/11 00:00 [received]
PHST- 2018/08/29 00:00 [revised]
PHST- 2018/08/30 00:00 [accepted]
PHST- 2018/09/07 06:00 [pubmed]
PHST- 2019/02/12 06:00 [medline]
PHST- 2018/09/07 06:00 [entrez]
AID - 10.1111/ejh.13170 [doi]
PST - ppublish
SO  - Eur J Haematol. 2018 Dec;101(6):750-757. doi: 10.1111/ejh.13170. Epub 2018 Oct 9.